Metastasis-associated protein 1 mRNA (MTA1 mRNA)

Metastasis-associated protein 1 (MTA1) mRNA is the transcript encoding the MTA1 protein, a pivotal component of the Nucleosome Remodeling and Deacetylase (NuRD) complex [1, 6]. This complex functions as a master epigenetic regulator, modulating gene expression through chromatin remodeling and histone deacetylation [1, 11]. MTA1 mRNA is frequently overexpressed in a broad spectrum of human malignancies, including breast, lung, and prostate cancers, where it serves as a key driver of aggressive tumor behavior and metastasis [1, 11]. By promoting the epithelial-mesenchymal transition (EMT) and enhancing cellular motility and invasion, high levels of MTA1 mRNA are strongly correlated with poor patient prognosis and therapeutic resistance [1, 13]. As a therapeutic target, MTA1 mRNA is primarily addressed through RNA-targeting modalities such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) [2, 16]. These agents utilize sequence-specific complementary pairing to induce the degradation of the mRNA transcript or inhibit its translation, thereby reducing the levels of the oncogenic MTA1 protein [14, 17]. Experimental studies have demonstrated that silencing MTA1 mRNA can effectively suppress tumor growth, angiogenesis, and metastatic spread in various preclinical models [13, 16]. However, therapeutic development faces challenges related to the systemic delivery of oligonucleotides and potential off-target effects on the physiological functions of MTA1 in normal tissues [7, 14].

Other names

Metastasis-associated 1 mRNAMTA1 transcriptMetastasis-associated gene 1 mRNA

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript to prevent translation of the MTA1 protein.